BGB-283

CAS No. 1446090-77-2

BGB-283( Lifirafenib | BGB 283 | BGB283 )

Catalog No. M11891 CAS No. 1446090-77-2

BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BGB-283
  • Note
    Research use only, not for human use.
  • Brief Description
    BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM).
  • Description
    BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM); inhibits recombinant BRAFV600E with IC50 of 23 nM; also inhibits EGFR and EGFR T790M/L858R with IC50 of 29 nM and 495 nM respectively; potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation in vitro; shows tumor growth inhibition in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation.Colon Cancer Preclinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Lifirafenib | BGB 283 | BGB283
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    Cancer
  • Indication
    Colon Cancer

Chemical Information

  • CAS Number
    1446090-77-2
  • Formula Weight
    478.4227
  • Molecular Formula
    C25H17F3N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 125 mg/mL
  • SMILES
    [H][C@@]1(C2=CC(OC3=C(CCC4=O)C(N4)=NC=C3)=CC=C2O[C@]51[H])[C@@H]5C6=NC7=CC=C(C=C7N6)C(F)(F)F
  • Chemical Name
    1,8-Naphthyridin-2(1H)-one, 5-[[(1R,1aS,6bR)-1a,6b-dihydro-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-cyclopropa[b]benzofuran-5-yl]oxy]-3,4-dihydro-, rel-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tang Z, et al. Mol Cancer Ther. 2015 Oct;14(10):2187-97. 2. Cancer Discov. 2016 Jul;6(7):OF1.
molnova catalog
related products
  • Sorafenib

    A potent, orally available Raf inhibitor with IC50 of 6, 22, and 38 nM for Raf-1, wt Braf, and BRaf V599E, respectively.

  • Dabrafenib

    Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

  • O4I2

    O4I2 is an effective Oct3/4 inducer in various human cell lines including human fibroblasts.